RU58841 powder is being discussed as a hair loss treatment, with concerns about its legitimacy and safety when purchased from Amazon. The conversation also mentions Minoxidil as a comparison in terms of price.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.
Pyrilutamide, a potential hair loss treatment, and how it compares to existing treatments such as Minoxidil, Finasteride and RU58841. Real-world results are being discussed to determine its effectiveness.
The user is using finasteride and minoxidil for hair loss but is looking for new treatments. Pyrilutamide and GT20029 are potential future treatments, with Pyrilutamide expected next year and GT20029 possibly by 2027.
RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.
OP experienced diffuse thinning for 11 years and used Minoxidil and Finasteride previously. They now use Pyrilutamide 0.5% and Alfatradiol 0.1%, resulting in significantly reduced hair loss.
The user is considering adding a topical treatment to their current regimen of finasteride and oral minoxidil to protect their temple area, with options like piro, RU58841, or topical finasteride or dutasteride. They are advised against overcomplicating their treatment, but another user suggests a topical with 8% minoxidil/dutasteride for better results.
A 21-year-old male is experiencing crown balding and is using RU58841, topical minoxidil, and plans to add dutasteride and oral minoxidil to his treatment. He seeks advice on increasing his treatment stack despite previous side effects like chest pain.
Significant hair regrowth was achieved after 4.5 months using 0.5 mg Dutasteride and 5 mg oral Minoxidil. Tips on obtaining prescriptions and discussions on effectiveness and side effects were also shared.
OP used minoxidil for 15 months and pyrilutamide for 46 days, achieving desired results without side effects. Users discussed alternatives like dutasteride and finasteride, with concerns about side effects like erectile dysfunction.
The user is considering using RU58841 and pyrilutamide for hair loss, debating between powder and topical forms, and is currently using a combination of dutasteride, finasteride, minoxidil, tretinoin, and supplements. They report no significant side effects from finasteride and dutasteride, and are seeing some hair growth, but not on the scalp.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
The user "AcanthocephalaNo7632" shared their progress with hair loss, mentioning the use of minoxidil and finasteride. Some users questioned the authenticity of the progress pictures.
The user is using 2.5mg oral minoxidil and Nizoral shampoo for hair regrowth, noticing some improvement. They are considering increasing the dosage and exploring alternatives to topical minoxidil/finasteride due to concerns about toxicity to cats.
The conversation is about finding a legitimate and affordable Chinese source for RU58841 powder for hair loss treatment. It suggests choosing a vendor with good reviews and testing the product for authenticity.
Dutasteride doses matter for hair loss treatment and are more effective than finasteride. RU58841 is suggested for better gains, but side effect profiles should be considered.
A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).
The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.
Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.
The user experienced severe side effects from finasteride, including cognitive and sexual issues, despite its effectiveness for hair growth. They are considering switching to RU58841 and seek insights from others who have made a similar change.
The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.
PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.
RU58841 may help some with hair loss, but it can have side effects like heart pain. Dutasteride and finasteride can cause initial shedding, and results may take time.
PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.